MX2023007036A - Formulaciones de liberacion prolongada para aplicaciones intra-articulares. - Google Patents

Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Info

Publication number
MX2023007036A
MX2023007036A MX2023007036A MX2023007036A MX2023007036A MX 2023007036 A MX2023007036 A MX 2023007036A MX 2023007036 A MX2023007036 A MX 2023007036A MX 2023007036 A MX2023007036 A MX 2023007036A MX 2023007036 A MX2023007036 A MX 2023007036A
Authority
MX
Mexico
Prior art keywords
intra
extended release
release formulations
oxabicyclo
dichlorophenyl
Prior art date
Application number
MX2023007036A
Other languages
English (en)
Inventor
Carlo Castagnoli
Andreas Fisch
Mathilde Lorscheider
Manjali Laxman Neharkar
Bernd Ulrich Riebesehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023007036A publication Critical patent/MX2023007036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende una suspensión acuosa de: (i) N-(3,4-diclorofenil)-3 -(piridin-4-il)-7-oxabiciclo[2.2.1]heptano-2-carboxamida cristalina o una sal farmacéuticamente aceptable de la misma; y (ii) un tensoactivo que comprende un copolímero soluble en agua caracterizado por > 5 % de solubilidad en agua a 25 °C. Las composiciones proveen la liberación prolongada de N-(3,4-diclorofenil)-3-(piridin-4-il)-7-oxabiciclo[2.2.1] heptano-2-carboxamida, y son adecuadas para la inyección intraarticular en una articulación de un paciente que sufre artritis, lesión articular o lesión de cartílago.
MX2023007036A 2017-11-10 2020-07-13 Formulaciones de liberacion prolongada para aplicaciones intra-articulares. MX2023007036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
MX2023007036A true MX2023007036A (es) 2023-06-28

Family

ID=64402238

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004477A MX2020004477A (es) 2017-11-10 2018-11-08 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
MX2023007036A MX2023007036A (es) 2017-11-10 2020-07-13 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004477A MX2020004477A (es) 2017-11-10 2018-11-08 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Country Status (12)

Country Link
US (1) US20210177824A1 (es)
EP (1) EP3706710B1 (es)
JP (1) JP7284750B2 (es)
KR (1) KR20200087138A (es)
CN (1) CN111278410A (es)
AU (1) AU2018364685B2 (es)
CA (1) CA3075722A1 (es)
CL (1) CL2020001156A1 (es)
IL (2) IL274149B2 (es)
MX (2) MX2020004477A (es)
TW (2) TW202400164A (es)
WO (1) WO2019092637A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3891154B1 (en) 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
EP4248950A4 (en) * 2020-11-30 2024-04-10 Lg Chemical Ltd INJECTABLE COMPOSITION CONTAINING CASPAS INHIBITOR AND MANUFACTURING METHOD THEREFOR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
KR102375396B1 (ko) * 2014-05-13 2022-03-18 노파르티스 아게 연골형성을 유도하기 위한 화합물 및 조성물

Also Published As

Publication number Publication date
IL274149A (en) 2020-06-30
IL274149B2 (en) 2024-02-01
IL274149B1 (en) 2023-10-01
RU2020115439A (ru) 2021-12-10
CA3075722A1 (en) 2019-05-16
MX2020004477A (es) 2020-08-03
EP3706710A1 (en) 2020-09-16
TW201922245A (zh) 2019-06-16
US20210177824A1 (en) 2021-06-17
AU2018364685B2 (en) 2021-05-20
CN111278410A (zh) 2020-06-12
AU2018364685A1 (en) 2020-03-26
CL2020001156A1 (es) 2020-10-30
JP2021502337A (ja) 2021-01-28
RU2020115439A3 (es) 2021-12-10
KR20200087138A (ko) 2020-07-20
TW202400164A (zh) 2024-01-01
EP3706710B1 (en) 2024-04-10
IL305541A (en) 2023-10-01
BR112020008806A2 (pt) 2020-10-20
TWI813597B (zh) 2023-09-01
JP7284750B2 (ja) 2023-05-31
WO2019092637A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2021004000A (es) Derivados de piperidina.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
MX2023007036A (es) Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
PH12019500822A1 (en) Crystalline forms of eravacycline
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.